BEIJING – Suzhou, China-based Ascentage Pharma Group Inc. said on Monday that it is working with Astrazeneca plc’s hematology R&D unit, Acerta Pharma, to develop a combination therapy of its Bcl-2 inhibitor, APG-2575, with Acerta's BTK inhibitor, Calquence (acalabrutinib). The first patient has been dosed in the U.S.

BEIJING – Diabetes-focused Hua Medicine (Shanghai) Ltd. became the first drugmaker to reveal phase III data of a glucokinase activator (GKA) designed to treat type 2 diabetes. On June 18, it said its first-in-class GKA, dorzagliatin, showed sustained efficacy and safety for the 52-week treatment period with reductions in HbA1c levels in a completed phase III trial as a monotherapy.

Clinical updates, including trial initiations, enrollment status and data readouts and publications: Aurinia, Azevan, Boehringer, Clover, Cohbar, Cyclerion, Cymabay, Finch, Genentech, Lilly, Nkamerica, Novartis, Novo, Otsuka, Reistone, Ridgeback, Sanofi, Uniqure.

Clinical updates, including trial initiations, enrollment status and data readouts and publications: Abbvie, Affiris, Aptinyx, Aribio, Eloxx, Genentech, Heat, Hua, Innovent, Lineage Cell, Pfizer, Sangamo, Seattle Genetics, Teva, Xeris.

Clinical updates, including trial initiations, enrollment status and data readouts and publications: Affimed, Akero, Ascentage, Ascletis, Astrazeneca, Atara, Biomarin, Biosig, Cara, Contrafect, Dare, Dynavax, Evgen, Inflarx, Kiniksa, Lilly, Merck, Nantpharma, Recordati, Remegen, Sagimet.

Clinical updates, including trial initiations, enrollment status and data readouts and publications: Affibody, Amylyx, Applied Therapeutics, Ardelyx, Atyr, Bayer, Beyondspring, Cardiff Oncology, Catalyst, Genentech, Glycomimetics, Humanigen, Immunic, Immunicum, Inventiva, Iveric, Kyowa Kirin, Lilly, Lundbeck, Momenta, Navidea, Oncimmune, Phathom, PTC, Roche, Sinovac, Solasia, Tarsus.

HONG KONG – Japan’s Seikagaku Corp. is contemplating the next move for its ONO-5704/SI-613 (diclofenac etalhyaluronate), a treatment for arthritis that it is co-developing with fellow Japanese company Ono Pharmaceutical Co. Ltd.

Clinical updates, including trial initiations, enrollment status and data readouts and publications: Addex, Amarin, Anavex, Arecor, Bionic Sight, Dermavant, Enb, Exicure, Forma, Humanigen, Immunicum, Janssen, Merck, Neuren, Oncopeptides, PDS, Pfizer, Provention, Renibus, Sanofi, Sarepta, Vyome.